PERSPECTIVE article
Front. Med.
Sec. Regulatory Science
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1598227
The regulatory and scientific context in the study of the Medicinal use of Cannabis in Peru
Provisionally accepted
- 1Clinic specialized in medical cannabis treatment CANNAVITAL, Lima, Peru
- 2Nesh Hubbs, Lima, Peru
- 3Norbert Wiener Private University, Lima, Lima, Peru
- 4Temuco Catholic University, Temuco, Araucania, Chile
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Cannabis has been historically utilized for medicinal purposes worldwide. However, it was classified as a controlled substance under the United Nations’ 1961 Single Convention on Narcotic Drugs, alongside coca and opium. This classification influenced many countries, including Peru, to adopt prohibitionist policies, even though the convention allowed medicinal use, scientific research, and even horticulture. Recent decades have witnessed a renewed interest in the therapeutic potential of cannabis, leading countries like Canada to establish medicinal frameworks. In 2017, Peru passed Law 30681, legalizing cannabis for medicinal use, scientific research, and pharmaceutical production through the obtention of licenses, and in 2021, Law 31312 allowed patient associations to grow and produce cannabis. Nevertheless, these regulations have proven insufficient, as no domestic production has taken place due to complex licensing requirements for both pharmaceutical companies and patient associations; the same scenario applies for scientific purposes. This article examines the regulatory challenges surrounding cannabis in Peru, focusing on scientific research. While the 2019 regulatory framework aimed to support medicinal access, it has fallen short in practice. Hard licensing process and stringent requirements have restricted scientific investigation, limiting it to observational studies and analysis of cannabis products available on the informal market. A recent study conducted between 2019 and 2023 analyzed native cannabis strains in four regions of Peru, highlighting the therapeutic potential of local cultivars. However, regulatory hurdles, such as sample obtention, transportation, and analysis, pose significant risks to researchers. The study suggests that Peru’s cannabis regulation requires urgent reforms.
Keywords: Cannabis, Medicinal Regulation, Peru, Scientific research, Cannabinoids
Received: 14 Apr 2025; Accepted: 20 Aug 2025.
Copyright: © 2025 Wong-Salgado, Moya-Salazar, Contreras-Pulache and Pardo- Villarroel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jeel Moya-Salazar, Nesh Hubbs, Lima, Peru
Hans Contreras-Pulache, Norbert Wiener Private University, Lima, 15046, Lima, Peru
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.